Volume 30, Number 3—March 2024
Research
Estimates of Incidence and Predictors of Fatiguing Illness after SARS-CoV-2 Infection
Quan M. Vu
, Annette L. Fitzpatrick, Jennifer R. Cope, Jeanne Bertolli, Nona Sotoodehnia, T. Eoin West, Nikki Gentile, and Elizabeth R. Unger
, Annette L. Fitzpatrick, Jennifer R. Cope, Jeanne Bertolli, Nona Sotoodehnia, T. Eoin West, Nikki Gentile, and Elizabeth R. Unger
Table 1
Characteristics of patients with COVID-19 and matched controls in study of incidence and predictors of fatiguing illness after SARS-CoV-2 infection, Washington, USA, February 2020–February 2021*
| Description | Patients, n = 4,589 | Controls, n = 9,022 |
|---|---|---|
| Age, y, mean (SD) |
49.5 (17.8) |
49.0 (18.0) |
| Sex | ||
| F | 2,248 (49.0) | 4,447 (49.3) |
| M |
2,341 (51.0) |
4,575 (50.7) |
| Race | ||
| Asian | 418 (9.1) | 807 (8.9) |
| Black | 704 (15.3) | 1136 (12.6) |
| Indian/Alaska native | 97 (2.1) | 153 (1.7) |
| Native Hawaiian Pacific | 82 (1.8) | 119 (1.3) |
| White | 2,942 (64.1) | 5,825 (64.6) |
| Missing |
346 (7.5) |
982 (10.9) |
| Ethnicity | ||
| Hispanic/Latino | 613 (13.4) | 1,166 (12.9) |
| Not Hispanic/Latino | 3,709 (80.8) | 7,033 (78.0) |
| Missing |
267 (5.8) |
823 (9.1) |
| Underlying conditions† | ||
| Acute myocardial infarction | 90 (2.0) | 147 (1.6) |
| History of myocardial infarction | 97 (2.1) | 149 (1.7) |
| Congestive heart failure | 289 (6.3) | 490 (5.4) |
| Peripheral vascular disease | 257 (5.6) | 451 (5.0) |
| Cerebrovascular disease | 231 (5.0) | 410 (4.5) |
| COPD | 667 (14.5) | 1,259 (14.0) |
| Dementia | 73 (1.6) | 122 (1.4) |
| Hemiplegia or paraplegia | 99 (2.2) | 178 (2.0) |
| Diabetes | 678 (14.8) | 1,262 (14.0) |
| Diabetes with complications | 354 (7.7) | 635 (7.0) |
| Moderate–severe renal disease | 400 (8.7) | 715 (7.9) |
| Mild liver disease | 318 (6.9) | 559 (6.2) |
| Moderate–severe liver disease | 46 (1.0) | 81 (0.9) |
| Peptic ulcer disease | 43 (0.9) | 71 (0.8) |
| Rheumatologic disease | 81 (1.8) | 128 (1.4) |
| HIV/AIDS | 129 (2.8) | 218 (2.4) |
| Any malignancy, except skin | 382 (8.3) | 677 (7.5) |
| Metastatic solid tumor | 111 (2.4) | 193 (2.1) |
*Values are no. (%) except as indicated. Race includes no information on Hispanic ethnicity. COPD, chronic obstructive pulmonary disease. †Diagnosed in the 18 mo before date of COVID-19 confirmation or date of negative test.
Page created: January 15, 2024
Page updated: February 22, 2024
Page reviewed: February 22, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.